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Abstract
Objective: To investigate factors contributing to excess deaths of older patients
during the initial 2020 lockdown beyond those attributable to confirmed COVID‐19.
Methods: Retrospective cohort study comparing patients treated between 23
March 2020 and 14 June 2020, deemed exposed to the pandemic/lockdown, to
patients treated between 18 December 2019 and 10 March 2020, deemed to be
unexposed. Data came from electronic clinical records from secondary care mental
health services in Cambridgeshire and Peterborough NHS Foundation Trust (CPFT),
UK (catchment area population ∼0.86 million). Eligible patients were aged 65 years
or over at baseline with at least 14 days' follow‐up, excluding patients diagnosed
with confirmed or suspected SARS‐CoV‐2 infection. The primary outcome was all‐
cause mortality.
Findings: In the two cohorts, 3,073 subjects were exposed to lockdown and 4,372
subjects were unexposed; the cohorts were followed up for an average of 74 and
78 days, respectively. After controlling for confounding by sociodemographic fac-
tors, smoking status, mental comorbidities, and physical comorbidities, patients with
dementia suffered an additional 53% risk of death (HR = 1.53, 95% CI = 1.02–2.31),
and patients with severe mental illness suffered an additional 123% risk of death
(HR = 2.23, 95% CI = 1.42–3.49). No significant additional mortality risks were
identified from physical comorbidities, potentially due to low statistical power in
that respect.
Conclusion: During lockdown people with dementia or severe mental illness had a
higher risk of death without confirmed COVID‐19. These data could inform future
health service responses and policymaking to help prevent avoidable excess death
during future outbreaks of this or a similar infectious disease.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
© 2021 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
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Key points
� Previous studies have explored the risk factors for death following COVID‐19 infection, but
data regarding the totality of excess deaths is sparse
� We conducted a retrospective cohort study based on a large clinical record database,
making a comparison with a historical control group
� We found that older people with dementia or serious mental illness had a higher risk of
death without confirmed COVID‐19 under the circumstance of lockdown
� This study could have an impact on existing health systems and clinical practice in response
to the excess death associated with COVID‐19 lockdown, and inform preparation for
possible future outbreaks
1 | BACKGROUND
The novel coronavirus disease COVID‐19 was declared a pandemic
by the World Health Organization on 11 March 2020.1 To minimize
the spread of COVID‐19, social isolation or social distancing (as part
of more general measures designed to cut infection, collectively
referred to as ‘lockdown’) have been implemented globally. The
United Kingdom (UK) implemented ‘social distancing’ from 16 March
2020 and more stringent measures, ‘lockdown’, from 23 March 2020.
During the lockdown, day‐to‐day contacts were reduced by requiring
people to stay at home, closing most businesses and venues, and
stopping all gatherings of more than two people in public.2 Increasing
evidence indicates that this has been an effective prevention and
control measure.3 However, besides the deaths directly attributable
to COVID‐19, a large number of extra indirect deaths have occurred
during lockdown.4–6 For example, in England and Wales, in addition
to the 45,511 deaths associated with COVID‐19 infection from 14
Mar 2020 to 29 May 2020, a further 12,522 excess deaths have been
reported.6 More detailed information about these excess deaths is
sparse, making it difficult to design strategies to ameliorate them. We
hypothesized that both physical diseases and mental disorders would
contribute.
We conducted a retrospective cohort study to identify which
previously documented factors were associated with excess death
during the lockdown, beyond those attributed to confirmed COVID‐19.
We focused on patients over the age of 65 as they represent the most
vulnerable population for death.5,6
2 | MATERIALS AND METHODS
2.1 | Study design and participants
We performed a retrospective cohort study using data from the
electronic clinical records of secondary care mental health services of
Cambridgeshire and Peterborough NHS Foundation Trust (CPFT),
which provides mental health and community physical health services
to a population of approximately 0.86 million people (18% of whom
are aged 65 years or over) in the UK. The present study focused on
patients in receipt of secondary care mental health services. CPFT's
electronic clinical records contain patient information recorded
during routine treatment, such as sociodemographic information,
smoking status, diagnosis, prescription data in free text, and death
status. Clinicians enter aspects of this information in a systematic and
structured/standard way to ensure its accuracy.7
For the cohort of patients exposed to lockdown, data collec-
tion began on 23 March 2020, and we used available data up to
14 June 2020. Data representing an unexposed cohort were
collected from 18 December 2019 to 10 March 2020. We took 10
March as the cut‐off date as there was already a widespread
concern with regards to coronavirus in the period immediately
prior to lockdown, which may already have been changing
behaviour. In order to keep the follow‐up duration consistent with
the exposed cohort, the starting point for the data collection of
the unexposed cohort was 18 December 2019. Eligible patients
were those aged 65 years or over at baseline and had at least two
weeks' (14 days') follow‐up. The origin time for each patient was
the start of data collection or their date of registration with CPFT
secondary care mental health services, whichever was latest.
Follow‐up was until the patients' final CPFT data was recorded,
the date of their death, or the study end date, whichever occurred
first. For the exposed cohort data, we excluded patients who were
diagnosed with confirmed or suspected SARS‐CoV‐2 infection
following the England official criteria.8
This study focuses on risk factors for deaths occurring after lock-
down among older adults known to secondary care mental health
services who did not have confirmed COVID‐19. It is impossible to
classify an individual death (where not directly attributed to COVID‐19)
as ‘excess’ or ‘expected’, but we analyse risk factors contributing
disproportionately to death after lockdown (more so than before
lockdown) via a statistical comparison with historical control periods,
described below.
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2.2 | Data collection
Data were extracted via the CPFT Research database (NHS Research
Ethics 17/EE/0442), specifically from a de‐identified copy of data
from CPFT's Servelec RiO electronic clinical records system, which
covers all CPFT secondary mental health services. The database
operates on an opt‐out basis, so has data on nearly all such CPFT
patients (at present totalling ∼208,000 across all ages). This database
includes sociodemographic variables, smoking status, death, and
documented morbidities (including mental disorders and physical
diseases). We examined the following sociodemographic variables:
age at baseline (years), gender (male vs. female), marital status
(married, cohabiting or civil partnership vs. not), and ethnicity (White
vs. others). Smoking status was defined as having been a current or
past smoker. Death was ascertained by weekly linkage to national
NHS Spine mortality data for all patients known to CPFT's RiO
system.
Comorbidities were judged based on World Health Organiza-
tion (WHO) International Statistical Classification of Diseases (ICD‐
10) diagnoses and on prescription information. Diagnoses were
presented in coded data. Medicine information was extracted from
free text using GATE‐based natural language processing (NLP)
software.9 The mental disorders we focused on included dementia
(recorded with ICD‐10 codes F00‐F03 and G30, or taking cholin-
esterase inhibitors or memantine), substance misuse (F10‐F19),
severe/serious mental illness (SMI) (F20‐F29, F30, and F31, or
taking antipsychotics, accepting that some antipsychotics could be
prescribed for other mental disorders), depression (F32 or F33, or
taking antidepressants), anxiety (F41 or F42), reaction to severe
stress (F43), eating disorders (F50), personality disorders (F60‐
F69), intellectual disability (F70‐F79), and intentional self‐harm
(X60‐X84). The physical diseases we focused on included dia-
betes mellitus (E10‐E14, or taking hypoglycaemic agents), circula-
tion system diseases (including hypertension or cardiovascular or
cerebrovascular disease, ICD‐10 codes I10‐I13, I15, I21‐I25, and
I60‐I69, or taking ACE inhibitors, angiotensin‐II receptor antago-
nists, beta blockers, calcium channel antagonists, or diuretics),
dyslipidemia (E78, or taking lipid‐lowering medications), respiratory
diseases (including asthma or chronic obstructive pulmonary dis-
ease [COPD], indicated by ICD‐10 codes J44 and J45, or taking
oral or inhaled corticosteroids, bronchodilators, or anti‐
inflammatory drugs used for airways disease, accepting that oral
corticosteroids may also indicate other inflammatory disorders),
and cancer (C00‐C97, or taking drugs implying cancer). Identifica-
tion of these diseases was based on historical CPFT records up to
one year before the origin time of follow up, except for lifelong
diseases including dementia, SMI, and the aforementioned physical
diseases. The medicines referred to were selected according to UK
National Institute for Health and Care Excellence (NICE) guide-
lines. See Table S1.
Data were complete for the outcome and for predictors, except
for ethnicity, and if diagnoses/medications were under‐coded (the
degree of undercoding not being directly measurable in this data set).
We omitted cases because of missing ethnicity, rather than
attempting to impute a value.
2.3 | Statistical analysis
To describe the baseline characterizes of this cohort, category vari-
ables were reported as number (percentage), and continuous vari-
ables were reported as mean (standard deviation).
Cox proportional hazard models were used to predict death by
risk factors. Risk factors such as sociodemographic variables, smoking
status, mental disorders, and physical diseases were treated as time‐
independent variables. A binary variable (exposed vs. unexposed) was
treated as a time‐dependent variable by controlling it as a stratifi-
cation factor in the Cox model. To examine whether associations
between risk factors and death changed under lockdown, in-
teractions between risk factors and this stratification factor were
included in the Cox model. Such an interaction, for a given risk factor,
judges whether its contribution to the risk of death differed before
versus after lockdown. The two cohorts were collected from the
same database (CPFT) but at different time periods. Participants in
the unexposed cohort would also be participants in the exposed
cohort, if they survived until 23 March 2020 (the start of the exposed
cohort period). We considered this overlap by performing the Cox
regression clustered on patients.
A full model with all risk factors and all interactions was fitted
first, then a stepwise process based on the Akaike information cri-
terion (AIC) was conducted. The model with the lowest AIC was
chosen as the final model.
We performed three sensitivity analyses. First, we required a
longer follow‐up (at least three weeks, 21 days) to exclude patients
registered in CPFT temporarily, such as visitors or people discharged
after a single assessment. Second, to control for a seasonal change
effect on the death toll, we also analysed data from the same period
of the previous two years, namely between 23 March 2019 and 14
June 2019 and between 23 March 2018 and 14 June 2018, as an
alternative unexposed group. Third, given the level of missing
ethnicity data, we repeated the analysis without ethnicity as a co-
variate, including those who had been excluded before.
Multicollinearity was tested using the variance inflation factor
(VIF). VIF ≥10 indicates a sign of severe or serious multicollinearity.10
In this study, all models had a maximum VIF of 2.3, suggesting a
negligible amount of multicollinearity.
We used R (version 3.5.0) for all analyses and defined statistical
significance as p < 0.05. Results are reported following the STROBE
checklist for cohort studies.11
2.4 | Role of the funding source
The funder of the study had no role in study design, data collection,
data analysis, data interpretation or writing of the article. SC, JL, and
RNC had full access to all the data in the study. The corresponding
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author had final responsibility for the decision to submit for
publication.
3 | RESULTS
After omitting cases because of missing ethnicity information
(omitted cases accounted for 11.7% in the lockdown‐exposed group
and 11.0% in the lockdown‐unexposed group), we followed 3,073
patients exposed to COVID‐19 lockdown during the pandemic and
4,372 patients before the COVID‐19 lockdown (unexposed group)
(Figure 1). The cohorts were followed up for an average of 74 and
78 days, respectively. In the cohort exposed to lockdown, there were
197 (6.4%) deaths that were not directly attributed to COVID‐19, a
significantly higher fraction (p = 0.0001) than in the unexposed
cohort (187%, 4.3%).
There were some minor differences in the baseline characteris-
tics of patients between the two cohorts (Table 1). Overall, patients
in the exposed cohort were slightly younger (mean age: 78.89 vs.
79.44 years), had less comorbid dementia (41.2% vs. 45.7%), had
more comorbid SMI (34.5% vs. 30%), and had more comorbid
depression (51% vs. 48%). No significant difference between the two
groups was observed for other characteristics, including gender,
marital status, ethnicity, smoking status, and other mental or physical
comorbidities.
After controlling for confounding by sociodemographic factors,
smoking status, other mental comorbidities, and physical comorbid-
ities, patients with dementia in the lockdown‐exposed group suffered
an additional 53% risk of death (HR = 1.53, 95% CI = 1.02‐2.31), and
patients with SMI suffered an additional 123% risk of death
(HR = 2.23, 95% CI = 1.42–3.49) (Figure 2). No significant additional
death risks were identified from physical comorbidities.
Sensitivity analyses using a longer follow‐up (Figure S1), to
exclude a seasonal effect (Figure S2), or considering people with
missing ethnicity data (Figure S3) all confirmed our primary results.
4 | DISCUSSION
4.1 | Principal findings and strengths
This study is the first to investigate risk factors contributing to excess
death among older patients of a mental health NHS Trust during the
lockdown. Using a retrospective cohort study based on a large and
comprehensive clinical record database, with comparison to a control
group, we found that older people with dementia or SMI had a higher
risk of excess death during lockdown. This is in contrast to previous
findings12–17 that physical comorbidities were the main risk factors
for death from COVID‐19 patients among the elderly. Unexpectedly,
physical diseases in this study were not identified as risk factors for
the excess death for those patients without confirmed COVID‐19
under the circumstance of lockdown (likely due to relatively low
power in that respect, as discussed below).
4.2 | Interpretation
Several other studies18,19 have focused on excess deaths, and the
US Centers for Disease Control and Prevention (CDC) have devel-
oped a method,20 based on the overdispersed Poisson distribution,
to calculate the number of excess deaths. By itself, this approach
provides information on the number of excess deaths. Our study
attempted to go beyond this by focusing on vulnerable populations
and asking which specific factors were associated with excess death,
not directly attributed to COVID‐19 (also by statistical comparison
to a historical control period). Such questions may be important in
practice to guide targeted policy formulation and resource
allocation.
Our results indicate that older people with dementia suffered an
increased likelihood of death during lockdown. Generally, individuals
with dementia are more likely to have chronic physical diseases21
such as diabetes and cardiovascular disease, and are more likely to
depend on family or caregivers as compared with their counterparts
without dementia.22 Despite controlling for these other known risk
factors for mortality from COVID‐19, dementia remained an inde-
pendent risk factor for excess death. This finding is to some extent in
keeping with another UK study suggesting that dementia is a rela-
tively strong risk factor for death from COVID‐19 in hospital
(HR = 1.79, 95% CI 1.67–1.93).23 One possibility is that these deaths
are due to unrecognized infection with SARS‐CoV‐2. This may not be
reflected in the recorded cause of death either, because the patient is
near the end of life with dementia (in which case dementia may be
recorded) or because the frail elderly have an atypical presentation
of infection.24,25 Many such patients stop eating and die relatively
rapidly without developing characteristic fever or cough, though
pathological testing has subsequently revealed infection with SARS‐
CoV‐2.24,25 Alternatively, the excess mortality may be due to indi-
rect effects of the coronavirus outbreak and not direct infection with
the virus. The lockdown may make daily support less available, and
therefore expose people to risks such as discontinuation of medica-
tion.22 During lockdown, social support has been reduced, which may
have increased loneliness and abandonment, perhaps particularly for
patients unable to understand the reasons for this, and this may
impact mortality.26–28 All of these could result in a worsening of
neuropsychiatric symptoms. Indeed, concerns have been expressed
that antipsychotic prescribing may increase to manage behavioural
disturbance in dementia during the COVID‐19 pandemic,29 and an-
tipsychotics increase mortality.30 It is also possible that these pa-
tients did not seek or receive the normal standard of care for their
physical co‐morbidities. Documented physical comorbidities were
not closely associated with mortality in this study, but the possibility
of undercoding of physical comorbidities in secondary care mental
health services remains (discussed further below), and in that
respect, and in terms of total sample size, our study may have been
underpowered to detect the effect of physical comorbidities, which
have been established in large‐scale population studies.23
Our findings also indicated that older people with SMI also
suffered an increased likelihood of death during lockdown. For
4 - CHEN ET AL.
people with SMI, the lockdown could further reduce and collapse
potentially already tenuous social networks,31,32 potentially exac-
erbating feelings of perplexity, anxiety, and paranoia.31,33 The
lockdown could also disrupt continuity of care,32 which is critical to
prevent decompensation and its consequences, such as mental and
physical deterioration, and even death.34 In addition, lockdown
could reduce patients' access to effective treatment;35 for example,
optimal care for schizophrenia includes assertive community
treatment and intensive case management, which emphasize in‐
person contacts.36 Telehealth might not add much value to care
as usual.37 As discussed above, a reduction in health‐seeking for
new‐onset physical disorders may have been contributory in this
group.
For both group of people with dementia or SMI, we cannot
exclude the possibility that lockdown increased their suicide rates, as
death certificate causes of death were not available (see below);
further evidence is required, but there has been no evidence for a
rise in suicide in England following lockdown.38,39
4.3 | Limitations
Our study's limitations include the following.
4.3.1 | Causes of death
We did not have data on causes of death (from the UK death certi-
fication process), and therefore could not study the detailed reasons
for excess death (not associated with documented COVID‐19 infec-
tion) in patients with dementia or SMI. This limitation needs attention
in future studies.
4.3.2 | Under‐recognition of COVID‐19
Patients with dementia or SMI may be groups with difficulties in
recognizing and reporting COVID‐19 symptoms. As discussed above,
death might be recorded but not mention coronavirus, even though it
might be a coronavirus‐related death. We have tried to reduce this
possibility by excluding patients with suspected as well as confirmed
COVID‐19.
4.3.3 | Under‐recording of COVID‐19
Although it is highly likely that all patients who were tested by CPFT
had their COVID‐19 status recorded, it is possible that patients were
17,029 paents registered in CFPT in exposed
group (aer COVID-19 lockdown, between 
March 23, 2020 and June 14, 2020)
3,073 Paents in lockdown exposed group 4,372 Paents In lockdown unexposed group
836 excluded because of follow-up me < 14 
days
4,354 paents
12,675 excluded because of inial follow-up 
age <65 years
3,518 paents
38 excluded because of diagnosis with 
confirmed or suspected SARS-CoV-2 infecon
22,719 paents registered in CFPT in 
unexposed group (before COVID-19 lockdown, 
December 18, 2019 to 10 March, 2020)
16,802 excluded because of inial follow-up 
age <65 years
1,005 excluded because of follow-up me < 14 
days
5,917  paents
407 excluded because of missing informaon 
on ethnicity
540 excluded because of missing informaon 
on ethnicity
3,480 paents 4,912 paents
F I GUR E 1 STROBE diagram showing construction of the cohorts
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diagnosed with COVID‐19 elsewhere and this was not reflected in
their CPFT records. We only included people with at least 14 days'
follow‐up, reducing the chance that people later diagnosed with
COVID‐19 were included. However, it is still possible that not all
such patients were excluded.
4.3.4 | Implications of a mental health service cohort
CPFT is a mental health and community NHS trust, providing both
physical and mental health services, and in this study we examined
data from patients over 65 known to secondary care mental health
services. An advantage is that CPFT sees a relatively high proportion
of those with severe mental illness. However, the low prevalence of
certain mental disorders (e.g. substance use, anxiety, reactions to
severe stress, and eating disorders), which may be due to secondary
care bias or undercoding, may have reduced power to detect an
effect of these conditions. A disadvantage is that physical disorders
may have been undercoded. We attempted to mitigate this by using
data derived from free text (as well as coded diagnoses) to detect
physical disorders, and by using up to a year's records to identify
physical diseases. However, the potential for undercoding may have
reduced power in this context.
4.3.5 | Community versus inpatient status
Our data included patients in the community (outpatients) and in-
patients, who may have had different vulnerabilities. However, the
psychiatric inpatient proportion was very small, so the present study
was primarily of a outpatient cohort; see Chen et al. (2020)40 for a
description of psychiatric inpatient numbers across all ages during
this period. We did not have data on acute hospital admissions for
our cohorts.
TAB L E 1 Patient characteristics
Variable Exposed group (n = 3,073) Unexposed group (n = 4,372) Test statistic p
Age (years) 78.89 (7.94) 79.44 (7.99) t = 2.929 0.0034
Gender (= male) 1277 (41.6%) 1824 (41.7%) χ2 = 0.014 0.9061
Marital status (= married, cohabiting or civil partnership) 1251 (40.7%) 1749 (40%) χ2 = 0.344 0.5576
Ethnicity (= White) 2908 (94.6%) 4142 (94.7%) χ2 = 0.024 0.8782
Smoker (= current or former) 83 (2.7%) 100 (2.3%) χ2 = 1.121 0.2897
Mental disorders
Dementia (= true) 1267 (41.2%) 1997 (45.7%) χ2 = 14.315 0.0002
Substance misuse (= true) 29 (0.9%) 33 (0.8%) χ2 = 0.568 0.4511
Severe mental illness (= true) 1059 (34.5%) 1312 (30%) χ2 = 16.277 0.0001
Depression (= true) 1567 (51%) 2097 (48%) χ2 = 6.500 0.0108
Anxiety (= true) 128 (4.2%) 171 (3.9%) χ2 = 0.240 0.6243
Reaction to severe stress (= true) 86 (2.8%) 103 (2.4%) χ2 = 1.256 0.2624
Eating disorder (= true) 4 (0.1%) 4 (0.1%) χ2 = 0.020 0.8869
Personality disorder (= true) 31 (1%) 36 (0.8%) χ2 = 0.503 0.4782
Intellectual disability (= true) 8 (0.3%) 9 (0.2%) χ2 = 0.057 0.8117
Intentional self‐harm (= true) 18 (0.6%) 23 (0.5%) χ2 = 0.034 0.8544
Physical diseases
Diabetes mellitus (= true) 496 (16.1%) 701 (16%) χ2 = 0.008 0.9272
Cardiovascular diseases (= true) 2173 (70.7%) 3097 (70.8%) χ2 = 0.008 0.9280
Cancer (= true) 52 (1.7%) 68 (1.6%) χ2 = 0.135 0.7129
Dyslipidemia (= true) 1436 (46.7%) 2047 (46.8%) χ2 = 0.003 0.9570
Respiratory diseases (= true) 470 (15.3%) 659 (15.1%) χ2 = 0.053 0.8186
Death (= true) 197 (6.4%) 187 (4.3%) χ2 = 16.358 0.0001
Follow‐up duration(days) 74.47 (20.07) 78.02 (16.11) t = 8.123 < 0.0001
Note: Data are shown as mean (standard deviation) or number (percentage). P values for age and time‐to‐event were obtained by t test, for eating
disorders via Fisher's exact test, and for others via Pearson's chi‐square test. Bold print in the final column indicates p < 0.05.
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4.3.6 | Residential setting
We were unable to control for patients' residential setting, since our
data did not include this. People with dementia are more likely to be
in care homes than those with SMI. People in living in semi‐shared
accommodation (such as care homes) may have a higher probability
of cross‐infection. We attempted to mitigate this by excluding people
with suspected as well as confirmed COVID‐19, but the influence of
missing information about residential setting, be it under‐ or over-
estimation, is unknown.
4.3.7 | Severity of comorbidities
The impact of severe diseases (e.g., advanced cancer, severe de-
mentia, uncontrolled diabetes) may be different from that exerted by
milder clinical conditions, but information was not available on the
severity of the chronic conditions we analysed.
4.3.8 | Winter comparator cohort
Using winter data as our “unexposed” group could have led to un-
derestimation of excess deaths, because more deaths occur among
the elderly during winter months (Dec‐Mar) than in other seasons.41
Our sensitivity analysis on seasonal effects to some extent confirmed
this: both dementia and SMI remained significant risk factors for
death (Figure S2), but the size of this effect in dementia was greatly
increased, and for SMI it was reduced.
4.3.9 | Potential for unrecognized early COVID‐19
The first COVID‐19 case was confirmed in the UK on 31 January
2020, and population behaviour may have changed even before the
lockdown; similarly, five COVID‐19 cases were recognized in our
region up to 10 March, but it is certainly likely that some early cases
went unrecognized, so some people with COVID‐19 may have been
in the “unexposed” cohort. However, such an effect would tend to
reduce power (by increasing mortality in the control cohort) rather
than produce a Type I error; likewise, the sensitivity analyses support
the consistency of our results.
4.3.10 | Cohort overlap
We analysed patients with an active case record and not solely new
referrals, and thus some patients may have been present in both
cohorts (particularly those receiving long‐term community care). As
discussed in the Methods, we considered this overlap via regression
clustered on patients.
4.3.11 | Generalizability
Our findings may not generalize. However, measures such as social
distancing and lockdown are being adopted in similar ways interna-
tionally, so the results of the present study may be useful for other
regions and countries.
5 | CONCLUSION
We report some of the factors associated with excess death in the
context of the COVID‐19 pandemic and the social measures to
prevent its spread. Dementia and SMI were identified as two major
risk factors for excess mortality in patients over 65 in receipt of
mental health services. We suggest this information could be used to
focus attention and resource on patients with dementia or SMI in
such circumstances. This should be used to support clinical guidelines
and policy at all levels during this outbreak and for any future
events.
F I GUR E 2 Adjusted hazard ratios (HR) for excess death during lockdown. Data are fitted by the Cox model. A binary variable (exposed vs.
unexposed) was treated as a time‐dependent variable and as a stratification factor in the Cox model. Risk factors' extra effects on death during
lockdown were tested via the interactions between risk factors and exposure. After model selection based on the Akaike information criterion
(AIC), the final predictive factors included in the Cox model were age, gender, marital status, ethnicity, dementia, serious/severe mental illness
(SMI), anxiety, diabetes, circulatory system diseases, exposure, dementia � exposure, SMI � exposure, and diabetes � exposure. Only the
results of the interactions are shown
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